PMID- 15010829
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20111117
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 24
IP  - 4
DP  - 2004 Apr
TI  - Dendritic cell-based immunotherapy of cancer with carcinoembryonic 
      antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients 
      with metastatic gastrointestinal or lung adenocarcinomas.
PG  - 909-17
AB  - We conducted a clinical study of cancer vaccine therapy with dendritic cells 
      (DCs) and HLA-A24-restricted carcinoembryonic antigen (CEA)-derived peptide to 
      assess the feasibility and efficacy of such therapy. Eighteen patients with 
      CEA-expressing metastatic gastrointestinal or lung adenocarcinomas who were 
      positive for human leukocyte antigen (HLA)-A24 were enrolled. DCs were generated 
      from the patients' autologous monocyte-enriched fractions of granulocyte 
      colony-stimulating factor-mobilized peripheral blood mononuclear cells in the 
      presence of granulocyte/macrophage colony-stimulating factor and interleukin-4. 
      The generated DCs were pulsed with CEA-derived, HLA-A24-restricted 9-mer peptide 
      (CEA652) and injected into the patients intradermally and subcutaneously every 2 
      weeks. Toxicity and clinical and immunological responses were closely monitored 
      in each patient. No severe toxicity directly attributable to the treatment was 
      observed, and the vaccine was well tolerated. Although no definite tumor 
      shrinkage occurred in any patient, long-term stable disease or marked decreases 
      in the serum CEA level were observed in some patients after therapy. Most of the 
      patients in whom treatment was clinically effective showed a positive skin 
      response to CEA652-pulsed DCs (delayed-type hypersensitivity skin test) and a 
      positive in vitro CTL response to CEA652 peptide after therapy. We conclude that 
      active specific immunotherapy using DCs pulsed with CEA652 is a safe and feasible 
      treatment that is clinically effective in some patients with metastatic 
      gastrointestinal or lung adenocarcinomas. Our results will hopefully encourage 
      further refinement and development of DC-based immunotherapy with 
      HLA-A24-restricted CEA-derived peptide for refractory solid cancers that express 
      CEA.
FAU - Ueda, Yuji
AU  - Ueda Y
AD  - Department of Surgery and Oncology of Digestive System, Graduate School of 
      Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. 
      yueda@koto.kpu-m.ac.jp
FAU - Itoh, Tsuyoshi
AU  - Itoh T
FAU - Nukaya, Ikuei
AU  - Nukaya I
FAU - Kawashima, Ichiro
AU  - Kawashima I
FAU - Okugawa, Kaori
AU  - Okugawa K
FAU - Yano, Yutaro
AU  - Yano Y
FAU - Yamamoto, Yoshiki
AU  - Yamamoto Y
FAU - Naitoh, Kei
AU  - Naitoh K
FAU - Shimizu, Keiji
AU  - Shimizu K
FAU - Imura, Kenichiro
AU  - Imura K
FAU - Fuji, Nobuaki
AU  - Fuji N
FAU - Fujiwara, Hitoshi
AU  - Fujiwara H
FAU - Ochiai, Toshiya
AU  - Ochiai T
FAU - Itoi, Hirosumi
AU  - Itoi H
FAU - Sonoyama, Teruhisa
AU  - Sonoyama T
FAU - Hagiwara, Akeo
AU  - Hagiwara A
FAU - Takesako, Kazutoh
AU  - Takesako K
FAU - Yamagishi, Hisakazu
AU  - Yamagishi H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adenocarcinoma/immunology/secondary/*therapy
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Carcinoembryonic Antigen/analysis/immunology
MH  - Dendritic Cells/*immunology
MH  - Feasibility Studies
MH  - Female
MH  - Gastrointestinal Neoplasms/immunology/secondary/*therapy
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - HLA-A Antigens/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Hypersensitivity, Delayed/etiology
MH  - *Immunotherapy
MH  - Lung Neoplasms/immunology/*therapy
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Treatment Outcome
EDAT- 2004/03/11 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/03/11 05:00
PHST- 2004/03/11 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/03/11 05:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2004 Apr;24(4):909-17.